Taking ketorolac (Toradol) with warfarin significantly increases your bleeding risk and is generally not recommended without careful medical oversight. Both FDA labeling and clinical evidence indicate this combination requires either avoiding ketorolac altogether or using it under close monitoring with possible warfarin dose adjustment. If you are on warfarin and need pain relief, your pharmacist or doctor should discuss safer alternatives before ketorolac is dispensed.
The FDA ketorolac drug label carries explicit warnings about anticoagulant use. Under the "Warnings and Precautions" section, ketorolac labeling states that NSAIDs "may increase the risk of serious GI adverse events, cardiovascular thrombotic events, and serious renal adverse events" and specifically cautions that "the concomitant use of NSAIDs with other drugs that affect coagulation (such as anticoagulants) may increase the risk of bleeding complications." The warfarin (Coumarin) label similarly warns that NSAIDs are among the drug classes that increase warfarin's anticoagulant effect through multiple mechanisms.
Neither drug is absolutely contraindicated with the other in FDA labeling, but both labels emphasize that concurrent use requires clinical judgment and monitoring. The key phrase in both labels is "use with caution," which in FDA regulatory language means the benefits must be carefully weighed against documented risks, and dosing or monitoring adjustments are often necessary.
Ketorolac's maximum duration of use is 5 days, which limits cumulative exposure, but even short-term use carries interaction risk with warfarin because the onset of the effect can be rapid.
The ketorolac-warfarin interaction occurs through three converging pharmacological pathways:
Both ketorolac and warfarin are highly protein-bound drugs (ketorolac ~99%, warfarin ~99%). When ketorolac enters the bloodstream, it competes for binding sites on plasma albumin. This displacement increases the concentration of unbound (active) warfarin, which is the form that exerts anticoagulant effect. A 5–10% increase in unbound warfarin can meaningfully elevate INR (International Normalized Ratio, the standard measure of anticoagulation).
Ketorolac, like all NSAIDs, irreversibly inhibits cyclooxygenase (COX) enzymes, particularly COX-1 in platelets. This blocks production of thromboxane A2, a potent platelet aggregator. This effect persists for the lifetime of the platelet (7–10 days for aspirin, slightly shorter for ketorolac). When combined with warfarin's inhibition of vitamin K-dependent clotting factors (II, VII, IX, X), the result is dual anticoagulant action—warfarin reduces clotting factor synthesis while ketorolac impairs platelet plug formation. This combination substantially raises bleeding risk.
NSAIDs reduce protective prostaglandins in the gastric mucosa and inhibit platelet aggregation in mucosal blood vessels. This increases risk of ulceration and bleeding. Warfarin amplifies this risk because even small GI bleeds may not clot effectively. The combination of anticoagulation and NSAID-induced mucosal injury creates a perfect storm for significant GI hemorrhage.
Ketorolac's potency as an NSAID is relevant here: it is one of the stronger NSAIDs on a milligram-for-milligram basis, which is why it is indicated only for short-term acute pain. Its intensity amplifies all three interaction mechanisms above.
Age and renal function: Patients over 65 with reduced renal clearance face heightened risk because ketorolac undergoes significant renal elimination. Reduced clearance prolongs drug exposure and amplifies the interaction. Warfarin's metabolism is hepatic, but renal disease often correlates with hepatic dysfunction in elderly patients.
History of GI bleeding: Any patient with prior peptic ulcer disease, gastritis, or GI bleeding is at substantially elevated risk. The combination of anticoagulation plus NSAID is contraindicated in this population even as a single dose.
Concurrent antiplatelet therapy: Patients on warfarin plus aspirin or clopidogrel who are then given ketorolac face triple anticoagulant/antiplatelet effect—a particularly dangerous scenario.
High warfarin intensity: Patients whose target INR is 2.5–3.5 (mechanical heart valve) are at higher baseline bleeding risk than those with INR target 2–3 (atrial fibrillation). Ketorolac-induced INR elevation is more clinically significant in high-intensity patients.
Liver disease or alcohol use: Patients with hepatic impairment have reduced warfarin metabolism, making them more INR-labile. Chronic alcohol use compounds this.
Acute kidney injury: Any episode of dehydration or acute renal injury during ketorolac use will reduce both drug's clearance, intensifying the interaction.
A 72-year-old man is on warfarin for atrial fibrillation (INR goal 2–3, currently therapeutic at 2.4) with stable dosing for 6 months. He undergoes a dental extraction under local anesthesia and experiences significant post-operative pain. The dentist prescribes ketorolac 30 mg IV for 5 days, unaware of the warfarin. After 48 hours, the patient notices increased bleeding from the extraction site that doesn't stop after 15 minutes of pressure. He calls his anticoagulation clinic and his INR is checked stat: it has risen to 4.2. He is counseled to discontinue ketorolac, increase oral vitamin K, and recheck INR in 48 hours. The INR gradually normalizes.
This scenario illustrates the rapid onset of the interaction (within 48 hours) and why immediate INR monitoring is essential if ketorolac is ever given to a warfarin patient. A safer approach would have been ibuprofen or acetaminophen, or proceeding without NSAID analgesia, at the time of the prescription.
A 68-year-old woman with Stage 3b chronic kidney disease (eGFR 35 mL/min) is on warfarin for a history of pulmonary embolism. She presents to urgent care with severe back strain and is prescribed ketorolac 30 mg four times daily for 3 days. The urgent care provider assumes 5-day total duration is safe. However, the patient's reduced renal clearance means ketorolac accumulates. By day 3, she experiences spontaneous epistaxis (nosebleed) and dark stools (melena). Her INR is 6.8, well above therapeutic. She requires reversal with fresh frozen plasma or prothrombin complex concentrate and hospitalization for GI evaluation (which confirms a small gastric ulcer). Ketorolac is permanently contraindicated.
This scenario emphasizes that ketorolac dosing must account for renal function, and even "standard" dosing in a renally impaired warfarin patient is unsafe.
Do not take ketorolac without explicit approval from the doctor or pharmacist managing your warfarin. If ketorolac is recommended:
When a warfarin patient requires acute pain management:
Check the full medication list to identify any other drug interactions. Ketorolac and aspirin interaction also carries significant bleeding risk, and warfarin and aspirin is a known combination that requires monitoring. Some patients may be on all three, which is high-risk.
Seek immediate medical attention if you experience any of the following while on warfarin and ketorolac:
Call your anticoagulation clinic or pharmacist before taking ketorolac, even if a doctor prescribed it. This is not a situation where you should wait for a side effect—proactive communication is critical.
Your medication safety is too important to leave to chance. If you are taking warfarin or any other medication, use checkdruginteractions.com to verify every new prescription, over-the-counter drug, and supplement against your full medication list. Our comprehensive database is powered by FDA labeling and clinical evidence, and it takes just seconds to check. Before you fill your next prescription or start a new medication, enter all your current drugs at checkdruginteractions.com and get a complete interaction report—because the combination that seems harmless might be the one that lands you in the hospital.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.